mRNA Therapeutics Market Report 2026

The mrna therapeutics market size has grown steadily in recent years. It will grow from $35.9 billion in 2025 to $37.18 billion in 2026 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to breakthrough success of mrna vaccines in infectious diseases, advances in nucleic acid delivery technologies, increased understanding of gene expression control, early research validation of mrna-based protein synthesis, strong public funding for mrna research platforms.

The mrna therapeutics market size is expected to see steady growth in the next few years. It will grow to $42.32 billion in 2030 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to rising demand for targeted and personalized therapies, expansion of mrna applications in oncology and rare diseases, growing biopharmaceutical investment in mrna pipelines, increasing number of mrna drugs entering clinical trials, strategic partnerships between biotech firms and research organizations. Major trends in the forecast period include expansion of mrna therapeutics beyond vaccines, growing focus on protein replacement therapies using mrna, rising clinical pipeline for non-vaccine mrna drugs, increasing investment in lipid nanoparticle delivery systems, acceleration of end-to-end mrna manufacturing capabilities.

The rising incidence of chronic and communicable diseases is anticipated to drive the growth of the mRNA therapeutics market in the coming years. Chronic and communicable diseases are conditions that endure over long periods and can be transmitted between individuals, including diseases such as tuberculosis, HIV/AIDS, and hepatitis. The increase in these diseases is largely attributed to factors such as greater global mobility and deficiencies in healthcare infrastructure, which lead to higher transmission rates and challenges in effective disease control. mRNA therapeutics aid in better disease management by quickly enabling the body to generate proteins that strengthen immune responses, supporting the rapid development of targeted vaccines and therapies. For example, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the growing prevalence of chronic and communicable diseases is fueling the expansion of the mRNA therapeutics market.

Major companies operating in the mRNA therapeutics market are concentrating on the development of advanced approaches, such as personalized neoantigen vaccines, to strengthen immune responses and enhance survival outcomes for cancer patients. Personalized neoantigen vaccines are individualized cancer treatments created for each patient by leveraging tumor-specific genetic mutations to activate the immune system to recognize and eliminate cancer cells. For example, in July 2023, Merck & Co., Inc., a US-based research-driven biopharmaceutical company, collaborated with Moderna Therapeutics, Inc., a US-based biotechnology firm, to launch a Phase 3 randomized clinical trial (V940-001) evaluating mRNA-4157 (V940) in combination with KEYTRUDA® (pembrolizumab) as an adjuvant therapy for patients with resected high-risk (Stage IIB-IV) melanoma. This trial builds on encouraging outcomes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, which demonstrated a significant advantage of the combination therapy over KEYTRUDA alone in lowering the risk of recurrence and distant metastasis. The Phase 3 study is designed to validate these results by measuring relapse-free survival and distant metastasis-free survival as the primary and secondary endpoints, respectively.

In June 2025, BioNTech SE, a biotechnology company based in Germany, acquired CureVac N.V. for an undisclosed sum. Through this acquisition, BioNTech SE seeks to enhance its capabilities in the research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy candidates, representing a significant milestone in its oncology strategy to accelerate innovative cancer therapies and set new standards of care in the years ahead. CureVac N.V. is a Germany-based company specializing in the development of mRNA-based therapies.

Major companies operating in the mrna therapeutics market are Pfizer Inc., Novartis AG, Sanofi AG, AstraZeneca plc, GlaxoSmithKline plc, Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd, Tiba Biotech LLC, CSPC Pharmaceutical Group, CRISPR Therapeutics AG.

North America was the largest region in the mRNA therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mrna therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the mRNA therapeutics market by increasing costs for importing specialized raw materials, lipid nanoparticles, enzymes, and bioprocessing equipment. These effects are most significant in regions reliant on global supply chains, particularly North America and Europe. Elevated production costs have influenced early-stage manufacturing and scale-up timelines. However, tariffs have also encouraged domestic manufacturing investments and regional supply chain localization, strengthening long-term market resilience.

The mrna therapeutics market research report is one of a series of new reports that provides mrna therapeutics market statistics, including mrna therapeutics industry global market size, regional shares, competitors with a mrna therapeutics market share, detailed mrna therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the mrna therapeutics industry. This mrna therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger RNA (mRNA) therapeutics refer to a form of medical treatment that uses messenger RNA (mRNA) molecules to enable the production of therapeutic proteins inside the body. These therapies are applied to prevent, manage, or cure diseases by instructing cells to synthesize specific proteins required to achieve desired therapeutic outcomes.

The primary products of mRNA therapeutics include vaccines and drugs. Vaccines within the mRNA therapeutics segment are pharmaceutical formulations that utilize messenger RNA to direct cells to produce specific proteins, thereby stimulating an immune response against targeted diseases. These products are applicable across a wide range of areas such as infectious diseases, oncology, rare genetic disorders, respiratory diseases, and others, with end users including hospitals and clinics, research organizations, and others.

The mRNA therapeutics market consists of revenues earned by entities by providing services such as vaccine development, protein replacement therapies, gene editing, monoclonal antibody production, and cancer treatment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.